According to Asthma UK, currently 5.4 million people suffer from asthma, however, “every day the lives of three families are devastated by the death of a loved one to an asthma attack, and tragically two thirds of these deaths are preventable”.
In 2016 in England and Wales alone, a shocking 1,237 people died from an asthma attack.
On November 29th 2017, NICE published the final guidelines on Asthma: diagnosis, monitoring and chronic asthma management, to improve asthma care, which included the NObreath® FeNO monitor from local manufacturer and second-generation family company, Bedfont Scientific Ltd., as a recommended device.
Bedfont has specialised in the design and manufacture of breath analysis medical devices for over 40 years and in 2017 their NObreath® FeNO monitor is celebrating 10 years of improving asthma management.
Bedfont have been campaigning vigorously to raise awareness of FeNO measuring and its benefits, especially after last year when asthma figures sparked increased concern; statistics released from Asthma UK which found that over 120,000 asthma sufferers in the UK are at risk from wrongly prescribed medication and NICE’s findings that 30% of people with asthma are suspected to have been misdiagnosed.
Asthma UK also found that “around 90,000 people in England, 6,000 in Wales, 7,000 in Scotland and 3,500 in Northern Ireland could have uncontrolled asthma that is not being monitored by health-care professionals.”
